CASI Pharmaceuticals (CASIF) Assets Average (2024 - 2025)
CASI Pharmaceuticals (CASIF) reported Assets Average of $25.1 million for Q4 2025, down 57.28% on a YoY basis from $58.6 million in Q4 2024, and down 9.97% quarter-over-quarter from $27.8 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Assets Average (2024 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported Assets Average for 2 years, with the latest figure at $25.1 million in Q4 2025.
- For the quarter ending Q4 2025, Assets Average fell 57.28% year-over-year to $25.1 million; the trailing twelve-month figure through Dec 2025 stood at $25.1 million (down 57.28% YoY), and the FY2025 full-year result was $39.7 million, down 38.48% from the prior year.
- Assets Average for Q4 2025 stood at $25.1 million, down from $27.8 million in the prior quarter.
- The five-year high for Assets Average was $66.6 million in Q1 2024, with the low at $15.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | 40.89 Mn |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | 26.03 Mn |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | 660.38 Mn |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | 25.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.06 Mn |
| Sep 30, 2025 | 27.83 Mn |
| Jun 30, 2025 | 15.62 Mn |
| Mar 31, 2025 | 26.86 Mn |
| Dec 31, 2024 | 58.65 Mn |
| Sep 30, 2024 | 31.83 Mn |
| Jun 30, 2024 | 29.03 Mn |
| Mar 31, 2024 | 66.64 Mn |